AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29603299 — intervention group
Group type: EXPERIMENTAL
Intervention: One-visit root canal treatment with 2% chlorhexidine (CHX) final rinse
Number of subjects: 90
Study 29603299 — intervention group
Group type: COMPARATOR
Intervention: Two-visit root canal treatment with calcium hydroxide (CH) dressing
Number of subjects: 90
Study 28004266 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde CTO-PCI
Number of subjects: 396
Study 28004266 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade CTO-PCI
Number of subjects: 396
Study 28004266 — intervention group
Group type: COMPARATOR
Intervention: Unsuccessful CTO-PCI
Number of subjects: 396
Study 28302101 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-grounded lifestyle intervention (weekly nutrition and wellness sessions, physical activity sessions twice a week for 6 months, followed by 3 months of booster sessions)
Number of subjects: 120
Study 28302101 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 24067873 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiplegic shoulder pain
Number of subjects: 14
Study 24067873 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive capsulitis
Number of subjects: 14
Study 24067873 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 14
Study 21415398 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection(s) plus a 4‐week therapy program
Number of subjects: 333
Study 21415398 — intervention group
Group type: COMPARATOR
Intervention: Therapy program alone
Number of subjects: 333
Study 19373973 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 590
Study 19373973 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 590
Study 19373973 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 590
Study 18075401 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-g EMLA cream applied 1 hour before the procedure
Number of subjects: 52
Study 18075401 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied 1 hour before the procedure
Number of subjects: 52
Study 18075401 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-g EMLA cream
Number of subjects: 52
Study 18075401 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 52
Study 14746532 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (Rituxan®)
Number of subjects: 0
Study 14746532 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (MabThera®)
Number of subjects: 0
Study 14746532 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab in combination with standard chemotherapy
Number of subjects: 0
Study 14746532 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 11683282 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous curettage
Number of subjects: 113
Study 11683282 — intervention group
Group type: COMPARATOR
Intervention: Injection of botulinum toxin A (BT-A)
Number of subjects: 113
Study 9564467 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate
Number of subjects: 0
Study 9564467 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 0
Study 9564467 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 0
Study 7797926 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated vaccination schedule (A; days 0, 10, 21)
Number of subjects: 270
Study 7797926 — intervention group
Group type: COMPARATOR
Intervention: Classic vaccination schedule (C; days 0, 28, 56)
Number of subjects: 270
Study 2204594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside and doxorubicin combined with etoposide (CTR III)
Number of subjects: 72
Study 2204594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside and doxorubicin combined with 6-thioguanine (DAT)
Number of subjects: 72
Study 625462 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrefined wheat diet
Number of subjects: 42
Study 625462 — intervention group
Group type: COMPARATOR
Intervention: Rice diet
Number of subjects: 42
Study 625462 — intervention group
Group type: COMPARATOR
Intervention: Varied rice diet (from another area)
Number of subjects: 42
Study 31229528 — intervention group
Group type: COMPARATOR
Intervention: Physical activity plus fatigue self-management intervention (FM+)
Number of subjects: 208
Study 31229528 — intervention group
Group type: COMPARATOR
Intervention: Physical activity-only intervention (PA-only)
Number of subjects: 208
Study 29806427 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional strapping reduction
Number of subjects: 32
Study 29806427 — intervention group
Group type: COMPARATOR
Intervention: Towel clamp reduction
Number of subjects: 32
Study 26124084 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy (75mg/m2 docetaxel d1, 75mg/m2 cisplatin d1, and 750mg/m2/day 5‐fluorouracil d1‐5) followed by radical surgery and post‐operative radiotherapy
Number of subjects: 256
Study 26124084 — intervention group
Group type: COMPARATOR
Intervention: Upfront radical surgery and post‐operative radiotherapy
Number of subjects: 256
Study 23404203 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer health coaching
Number of subjects: 299
Study 23404203 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 299
Study 22025880 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic goat yogurt with 10(9) CFU/mL Bifidobacterium longum
Number of subjects: 59
Study 22025880 — intervention group
Group type: COMPARATOR
Intervention: Formula yogurt (without probiotics)
Number of subjects: 59
Study 18481713 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at 3-5 of the most severe tender points
Number of subjects: 66
Study 18481713 — intervention group
Group type: COMPARATOR
Intervention: Medication group (oral administration according to WHO Three Step Administration Principle: aspirin for mild pain, codeine for moderate pain, morphine for severe pain)
Number of subjects: 66
Study 16816757 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural ropivacaine 0.3%
Number of subjects: 30
Study 16816757 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous morphine
Number of subjects: 30
Study 14579873 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype power toothbrush (Crest SpinBrush Pro)
Number of subjects: 40
Study 14579873 — intervention group
Group type: COMPARATOR
Intervention: Control manual toothbrush (Oral-B Cross Action)
Number of subjects: 40
Study 10763793 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist nurse interventions including information, advice, support, and monitoring
Number of subjects: 101
Study 10763793 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration with 17 other professional groups
Number of subjects: 101
Study 1953532 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vaccine containing killed Haemophilus influenzae
Number of subjects: 64
Study 1953532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 7447203 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose verapamil (0.075 mg/kg body weight)
Number of subjects: 50
Study 7447203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7447203 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose verapamil (0.15 mg/kg body weight)
Number of subjects: 50
Study 31502906 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Screening and Referral (ESR)
Number of subjects: 235
Study 31502906 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Support for Progress (PSP)
Number of subjects: 235
Study 30448451 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp) once-daily (OD)
Number of subjects: 0
Study 30448451 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar) U100 + insulin aspart (IAsp) once-daily (OD)
Number of subjects: 0
Study 30448451 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegAsp
Number of subjects: 0
Study 30448451 — intervention group
Group type: COMPARATOR
Intervention: IGlar U100 + IAsp
Number of subjects: 0
Study 29482955 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable orthosis
Number of subjects: 249
Study 29482955 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonremovable orthosis
Number of subjects: 249
Study 29482955 — intervention group
Group type: COMPARATOR
Intervention: No orthosis
Number of subjects: 249
Study 26896686 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervarix™ HPV vaccine
Number of subjects: 91
Study 26896686 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardasil™ HPV vaccine
Number of subjects: 91
Study 26896686 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 91
Study 24502766 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary arginine supplementation (0% vs. 1%)
Number of subjects: 54
Study 24502766 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced protein diet (RPD)
Number of subjects: 54
Study 24502766 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine supplementation of RPD
Number of subjects: 54
Study 24502766 — intervention group
Group type: COMPARATOR
Intervention: Normal protein diet (NPD)
Number of subjects: 54
Study 22901446 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group (BMI ≥ 30)
Number of subjects: 300
Study 22901446 — intervention group
Group type: COMPARATOR
Intervention: Nonobese group (BMI < 30)
Number of subjects: 300
Study 22901446 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 300
Study 20308489 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Weight (BW) group with contrast dose of 360 mg I/kg BW
Number of subjects: 89
Study 20308489 — intervention group
Group type: COMPARATOR
Intervention: Body Surface Area (BSA) group with contrast dose of 12,753 mg I/m(2) BSA
Number of subjects: 89
Study 17369673 — intervention group
Group type: EXPERIMENTAL
Intervention: Various forms of cancer trials organized by the British Medical Research Council (MRC)
Number of subjects: 0
Study 17369673 — intervention group
Group type: COMPARATOR
Intervention: Surgery as the dominant form of therapy
Number of subjects: 0
Study 15585553 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal band restriction
Number of subjects: 34
Study 15585553 — intervention group
Group type: COMPARATOR
Intervention: Reduced band restriction
Number of subjects: 34
Study 15585553 — intervention group
Group type: EXPERIMENTAL
Intervention: LAGB subjects
Number of subjects: 34
Study 15585553 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 34
Study 12395978 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg alone
Number of subjects: 18
Study 12395978 — intervention group
Group type: COMPARATOR
Intervention: Nateglinide 120 mg alone
Number of subjects: 18
Study 12395978 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant nateglinide 120 mg and diclofenac 75 mg
Number of subjects: 18
Study 10048900 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose nandrolone decanoate (65 mg/week)
Number of subjects: 18
Study 10048900 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose nandrolone decanoate (200 mg/week)
Number of subjects: 18
Study 10048900 — intervention group
Group type: COMPARATOR
Intervention: Placebo (i.m.)
Number of subjects: 18
Study 10048900 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone treatment (both doses)
Number of subjects: 18
Study 10048900 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate therapy (12-week open-label follow-up)
Number of subjects: 18
Study 7762853 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirfentanil
Number of subjects: 18
Study 7762853 — intervention group
Group type: COMPARATOR
Intervention: Butorphanol
Number of subjects: 18
Study 2212180 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instructional guide about AIDS and its transmission with group instruction
Number of subjects: 60
Study 2212180 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instructional guide about AIDS and its transmission without group instruction
Number of subjects: 60
Study 2212180 — intervention group
Group type: COMPARATOR
Intervention: Control condition (neither guide nor group instruction)
Number of subjects: 60
Study 7039004 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA)
Number of subjects: 124
Study 7039004 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone
Number of subjects: 124
Study 7039004 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 124
Study 31599827 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-discontinuation
Number of subjects: 157
Study 31599827 — intervention group
Group type: COMPARATOR
Intervention: Office discontinuation
Number of subjects: 157
Study 30339989 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting the Ultra-poor (TUP) program
Number of subjects: 0
Study 30339989 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-participant households)
Number of subjects: 0
Study 27338456 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 400 μg (two times/daily) for three months
Number of subjects: 66
Study 27338456 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 66
Study 27338456 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid intervention
Number of subjects: 66
Study 25042159 — intervention group
Group type: EXPERIMENTAL
Intervention: iPad use (investigational group)
Number of subjects: 30
Study 25042159 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 30
Study 22493925 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuina treatment (local manipulations on breasts combined with acupoint manipulations)
Number of subjects: 84
Study 22493925 — intervention group
Group type: COMPARATOR
Intervention: Control group (rooming-in conventional managements)
Number of subjects: 84
Study 22493925 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuina treatment
Number of subjects: 84
Study 22493925 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 20565790 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 sessions of acupuncture plus usual GP care
Number of subjects: 220
Study 20565790 — intervention group
Group type: COMPARATOR
Intervention: Usual GP care alone
Number of subjects: 220
Study 20565790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis at 12 months
Number of subjects: 220
Study 18202422 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (100 mg/m²) with carboplatin (AUC = 6 mg/mL x min)
Number of subjects: 444
Study 18202422 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of paclitaxel (225 mg/m²) and carboplatin (AUC = 6) every 3 weeks
Number of subjects: 444
Study 15700191 — intervention group
Group type: EXPERIMENTAL
Intervention: IOP-lowering therapy
Number of subjects: 129
Study 15700191 — intervention group
Group type: COMPARATOR
Intervention: No IOP-lowering therapy
Number of subjects: 129
Study 12618969 — intervention group
Group type: EXPERIMENTAL
Intervention: Condylar positioning devices
Number of subjects: 30
Study 12618969 — intervention group
Group type: COMPARATOR
Intervention: Alternative method for intraoperative assessment of mandibular repositioning
Number of subjects: 30
Study 10626564 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen therapy initiated at 12 years of age
Number of subjects: 0
Study 10626564 — intervention group
Group type: COMPARATOR
Intervention: Oestrogen therapy initiated at 15 years of age
Number of subjects: 0
Study 10626564 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 0
Study 8529507 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 0
Study 8529507 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 0
Study 8529507 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (in severe patients treated by large doses of glibenclamide)
Number of subjects: 0
Study 1949925 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg i.v.
Number of subjects: 52
Study 1949925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 7023863 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised three-month running program
Number of subjects: 31
Study 7023863 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 31
Study 31026534 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa therapy
Number of subjects: 24
Study 31026534 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 24
Study 31026534 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa therapy (ON-medication condition)
Number of subjects: 24
Study 31026534 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa therapy (OFF-medication condition)
Number of subjects: 24
Study 27734202 — intervention group
Group type: EXPERIMENTAL
Intervention: FLS training platform
Number of subjects: 39
Study 27734202 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-FLS platform
Number of subjects: 39
Study 26220734 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 1153
Study 26220734 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum amyloid A (SAA)
Number of subjects: 1153
Study 26220734 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble tumor necrosis factor receptor‐2 (sTNFRII)
Number of subjects: 1153
Study 26220734 — intervention group
Group type: EXPERIMENTAL
Intervention: Monokine induced by gamma interferon (CXCL9/MIG)
Number of subjects: 1153
Study 26220734 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation score combining CRP, SAA, sTNFRII, and CXCL9/MIG
Number of subjects: 1153
Study 25428509 — intervention group
Group type: COMPARATOR
Intervention: Education-only
Number of subjects: 188
Study 25428509 — intervention group
Group type: COMPARATOR
Intervention: Group-based support
Number of subjects: 188
Study 25428509 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 188
Study 21668788 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral-fixated posterior chamber intraocular lens
Number of subjects: 49
Study 21668788 — intervention group
Group type: EXPERIMENTAL
Intervention: Iris-fixated anterior chamber intraocular lens
Number of subjects: 49
Study 19671303 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS treatment at acupoints ST36 (Zusanli) and PC6 (Neiguan) twice a day for 2 weeks
Number of subjects: 39
Study 19671303 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS treatment
Number of subjects: 39
Study 19671303 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS treatment
Number of subjects: 39
Study 17332097 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cup positioning system
Number of subjects: 60
Study 17332097 — intervention group
Group type: COMPARATOR
Intervention: Freehand cup positioning
Number of subjects: 60
Study 15777070 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 1200 IU daily
Number of subjects: 0
Study 9581727 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g three times daily)
Number of subjects: 48
Study 9581727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 7994817 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin inhibitor remikiren
Number of subjects: 36
Study 7994817 — intervention group
Group type: EXPERIMENTAL
Intervention: Converting enzyme inhibitor enalaprilat
Number of subjects: 36
Study 7994817 — intervention group
Group type: COMPARATOR
Intervention: Combination of remikiren and enalaprilat
Number of subjects: 36
Study 7994817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 2662790 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous catheter drainage
Number of subjects: 50
Study 2662790 — intervention group
Group type: COMPARATOR
Intervention: Repeat trial of conservative therapy
Number of subjects: 50
Study 2662790 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic needle aspirations
Number of subjects: 50
Study 2662790 — intervention group
Group type: COMPARATOR
Intervention: Open surgical drainage
Number of subjects: 50
Study 8956 — intervention group
Group type: EXPERIMENTAL
Intervention: Dibenzepine
Number of subjects: 0
Study 8956 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30875343 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT plus 5 mg/d donepezil
Number of subjects: 0
Study 30875343 — intervention group
Group type: COMPARATOR
Intervention: ECT with placebo
Number of subjects: 0
Study 29169373 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing of hypertensive medication
Number of subjects: 21116
Study 29169373 — intervention group
Group type: COMPARATOR
Intervention: Evening dosing of hypertensive medication
Number of subjects: 21116
Study 26427805 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF) - 1.1Gy+2Gy per day, 5 days/week for 4.5 weeks, total dose 68Gy
Number of subjects: 0
Study 26427805 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF) - 2Gy per day, 5 days/week for 7 weeks, total dose 68Gy
Number of subjects: 0
Study 26427805 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF)
Number of subjects: 0
Study 26427805 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF)
Number of subjects: 0
Study 24127763 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-Based Learning (CBL)
Number of subjects: 40
Study 24127763 — intervention group
Group type: COMPARATOR
Intervention: Lecture-Based Education (LBE)
Number of subjects: 40
Study 21673197 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual cup
Number of subjects: 110
Study 21673197 — intervention group
Group type: COMPARATOR
Intervention: Tampons
Number of subjects: 110
Study 18422441 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g valacyclovir TID for 7 days
Number of subjects: 87
Study 18422441 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g valacyclovir TID for 7 days
Number of subjects: 87
Study 18422441 — intervention group
Group type: COMPARATOR
Intervention: 800 mg acyclovir 5 times per day for 7 days (previous study)
Number of subjects: 87